COVID-19 in Elderly Patients with Acute Kidney Injury

COVID-19 in Elderly Patients with Acute Kidney Injury

Yavuz AYAR¹, Olgun Deniz², Baris DONER¹, Isa KILIC³, Canan DEMIR⁴, Abdulkadir SAHIN⁵

¹University of Health Sciences, Bursa Faculty of Medicine, Department of Nephrology and Internal Medicine, Bursa, Turkey.

²University of Health Sciences, Bursa Faculty of Medicine, Department of Geriatrics, Bursa, Turkey.

³University of Health Sciences, Bursa Faculty of Medicine, Department of Intensive Care, Anesthesia and Reanimation, Bursa, Turkey.

⁴University of Health Sciences, Bursa Faculty of Medicine, Department of Clinical Microbiology and Infection Diseases, Bursa, Turkey.

⁵University of Health Sciences, Bursa Faculty of Medicine, Department of Internal Medicine, Bursa, Turkey.

Corresponding Author: Yavuz AYAR, University of Health Sciences, Bursa Faculty of Medicine, Department of Nephrology and Internal Medicine, Dogankoy mevki, Nilufer/BURSA.

Tel No: +90 5055416075

Email: yavuzayar@hotmail.com

Olgun DENIZ, University of Health Sciences, Bursa Faculty of Medicine, Department of Geriatrics, Dogankoy mevki, Nilufer/BURSA.

Tel No: +90 535 6889477

Email: olgundeniz2001@yahoo.com

Baris DONER, University of Health Sciences, Bursa Faculty of Medicine, Department of Nephrology, Dogankoy mevki, Nilufer/BURSA.

Tel No: +90 533 2661232

Email: drbarisdoner@yahoo.com

Isa KILIC, University of Health Sciences, Bursa Faculty of Medicine, Department of Intensive Care, Anesthesia and Reanimation, Dogankoy mevki, Nilufer/BURSA.

Tel No: +90 505 3513835

Email: kilicisaicu@gmail.com

Canan DEMIR, University of Health Sciences, Bursa Faculty of Medicine, Department of Clinical Microbiology and Infection Diseases, Dogankoy mevki, Nilufer/BURSA.

Tel No: +90 541 9525447

Email: drcanandemir@hotmail.com

Abdulkadir SAHIN, University of Health Sciences, Bursa Faculty of Medicine, Department of Internal Medicine, Dogankoy mevki, Nilufer/BURSA.

Tel No: +90 506 3305643

Email: draksca@gmail.com

ACKNOWLEDGEMENT

DECLERATIONS

Conflict of interest

None

Source of funding

None

ABSTRACT

Objective: Coronavirus disease 2019 (Covid 19) started in China in December 2019 and spread all over the world, is more progressive in patients who are elderly and with chronic diseases. Especially kidney involvement affects the survival of patients. In this study, we analyzed Covid 19 patients who developed acute kidney injury treated in our unit, retrospectively.

Materials: The clinical and laboratory data of 610 patients who hospitalized due to Covid 19 pandemic between 01.06.2020 and 30.06.2021 in the intensive care and other clinics of our hospital evaluated from the records, retrospectively. One hundred-fourty patients diagnosed with AKI according to the criteria of KDIGO (Kidney Disease Global Outcomes). The patients divided into two groups as KDIGO stage 1 and 2, 3.

Results: The median age in both groups was 70 (35-92) and 73 (35-90) years. Approximately seventy percent of them were over 65 years old. Almost all of the patients had hypertension. Most of the patients were using angiotensin converting enzyme inhibitors (ACE inh) or angiotensin receptor blockers (ARB) (84%). AKI was present at the time of admission (61.9%) in the KDIGO 1 group and at the time of hospitalization (64.3%) in the KDIGO 2, 3 group. The mortality rate was higher in stage 2-3 AKI patients (35.7%). Ferritin and fibrinogen levels were high in the KDIGO 2, 3 group, while lymphocyte levels were low.

Conclusion: AKI can be seen at the time of admission and during treatment in patients who are hospitalized and treated due to Covid 19. Covid 19 is more mortal in patients with advanced AKI.

Keywords: Covid-19, acute kidney injury, mortality.

INTRODUCTION

Coronavirus disease 2019 (Covid 19) started to affect the world with the end of 2019. As a global pandemic, it resulted in more than 175 million cases and approximately 3.8 million deaths as of June 13 (1). Acute kidney injury (AKI) in Covid 19 patients varies from country to country, from region to region, but is observed between 10-15%, and this rate reaches up to 50% in patients hospitalized in the intensive care unit. AKI has a serious course especially in patients hospitalized in the intensive care unit, leading to prolonged hospitalizations and increased mortality (2-4).

The aim of our study was to evaluate the clinical and laboratory data, risk factors affecting prognosis and mortality of patients hospitalized for AKI in a tertiary healthcare institution.

MATERIALS and METHODS

Patients

The data of 610 patients over the age of 18 who admitted to our hospital and hospitalized in intensive care unit and clinics between 01.06.2020 and 30.06.2021 due to Covid 19 evaluated retrospectively. According to Kidney Disease Global Outcomes (KDIGO) AKI guidelines (Table 1), patients diagnosed with AKI and divided into two groups as KDIGO 1 and KDIGO 2, 3. The clinical and laboratory data of the patients analyzed.

Table 1. Staging of acute kidney injury according to KDIGO guideline (5).

Stage 1	Serum creatinine	Urine output
---------	------------------	--------------

1	1.5–1.9 times baseline OR ≥ 0.3 mg/dl (≥ 26.5 mmol/l) increase	<0.5 ml/kg/h for 6– 12 hours
2	2.0–2.9 times baseline	<0.5 ml/kg/h for ≥ 12 hours
3	3.0 times baseline	<0.3 ml/kg/h for ≥ 24 hours
	OR	OR
	Increase in serum creatinine to 4.0 mg/dl (≥ 353.6 mmol/l)	Anuria for ≥ 12 hours
	OR	
	Initiation of renal replacement therapy	
	OR, In patients <18 years, decrease in eGFR to <35 ml/min per 1.73 m ²	

Biostatistical analysis

Statistical analysis was carried out using the Statistical Package for the social sciences (SPSS) version 21.0 (IBM, Armonk, NY, USA) software program. Continuous variables were assessed by Kolmogorov-Smirnov test and histograms to find out if they had normal or skewed distribution. Continuous skew-distributed variables were compared with the Mann–Whitney *U*-test between the two groups, and variables with normal distribution were compared with independent variables *t*-test between the two groups. Categorical variables were compared by Chi-square or Fisher Exact tests, where appropriate. Categorical variables were presented as number and frequency. P-value < 0.05 was considered statistically significant.

RESULTS

Approximately 23% (140 patients) of 610 patients admitted to the hospital diagnosed with AKI according to the KDIGO AKI guidelines. Most of the patients defined as stage 1 AKI (80%). The number of patients over 65 years of age in both groups was 67.9%. As an additional disease, 97% of AKI patients had hypertension. Eighty four percent of the patients were using angiotensin converting enzyme inhibitors (ACEinh) or angiotensin receptor blockers (ARB) as antihypertensive therapy, 75% of the patients were using antiaggregant or anticoagulant therapy. The number of patients with diabetes (39.3%) and using insulin

(28.6%) were higher in the KDIGO 1 group. The duration of AKI was 5 (2-25) days in the KDIGO 1 group and 7 (2-25) days in the KDIGO 2, 3 group and did not differ. AKI development during hospitalization was higher in the KDIGO 2,3 group (61.9%), and AKI at admission was more common in the KDIGO 1 group (64.3%) ($p=0.003$ and 0.013 , respectively). Mortality was 35.7% higher in the KDIGO 2.3 group ($p=0.001$). Ferritin and fibrinogen levels, as markers of infection and inflammation, increased more in the KDIGO 2, 3 group ($p=0.042$ and 0.017 , respectively). Lymphocyte count and oxygen saturation were lower in the same group ($p<0.001$ and 0.002 , respectively). Clinical and laboratory findings are summarized in Table 2.

Table 2. Characteristics and laboratory findings in both groups.

	KDIGO stage 1 (n=112)	KDIGO stage 2 and 3 (n=28)	p
Age, median (min-max)	70 (35-92)	73 (35-90)	0.630
Age $\geq$ 65, n (%)	76 (67.9)	76 (67.9)	1
Diabetes Mellitus, n (%)	44 (39.3)	8 (28.6)	0.294
Hypertension, n (%)	109 (97.3)	27 (96.4)	0.800
Chronic Kidney Disease, n (%)	26 (23.2)	6 (21.4)	0.840
Obesity, n (%)	2 (1.8)	1 (3.6)	0.491
Chronic Obstructive Pulmonary Disease, n (%)	16 (14.3)	3 (10.7)	0.765
Coronary Artery Disease, n (%)	46 (41.1)	11 (39.3)	0.863
Heart Failure, n (%)	33 (29.5)	4 (14.3)	0.103
Cerebrovascular Disease, n (%)	6 (5.4)	3 (10.7)	0.383
Malignity, n (%)	13 (11.6)	7 (25)	0.126
Chronic liver disease, n (%)	2 (1.8)	0 (0)	0.476
Medications			
-ACE inh, n (%)	54 (48.2)	13 (46.4)	0.866
-ARB, n (%)	41 (36.6)	10 (35.7)	0.930
-CCB, n (%)	42 (37.5)	10 (35.7)	0.861
-BB, n (%)	72 (64.3)	13 (46.4)	0.084
-Insulin, n (%)	32 (28.6)	3 (10.7)	0.051
-OAD, n (%)	13 (11.6)	5 (17.9)	0.359
-Antiagregan, n (%)	78 (69.6)	16 (57.1)	0.208
-Anticoagulan, n (%)	9 (8)	2 (7.1)	0.875
Duration of acute kidney injury, n (%)	5 (2-25) (n =39)	7 (2-25) (n =16)	0.386
Acute renal failure			
-during hospitalization, n (%)	38 (33.9)	18 (64.3)	0.003
-at admission, n (%)	69 (61.9)	10 (35.7)	0.013

AKI on CKD	26 (23.2)	6 (21.4)	0.626
AKI progression, n (%)	10 (8.9)	11 (39.3)	<0.001
Mortality, n (%)	9 (8)	10 (35.7)	0.001
Duration of intensive care unit, median (min-max)	8 (2-45)	6 (1-21)	0.546
Ferritin (µg/l)	304.10 (23.40 – 2000)	517.50 (74.10 – 2000)	0.042
Lenfosit (10 ³ /µl)	1.32 (0.24 – 4.92)	0.89 (0.06 – 2.13)	< 0.001
D dimer (µg/ml)	9.50 (1.5-92.2)	10.2 (2-91.6)	0.306
Fibrinogen (mg/dl)	424 (148-900)	511.50 (189-900)	0.017
Serum creatinine (mg/dl)	1.47 (0.56-5.35)	1.43 (0.56-8.38)	0.942
Serum Na (mmol/l)	137 ± 4.9	136 ± 4.9	0.206
Serum albumin (g/dl)	3.45 ± 0.47	3.32 ± 0.44	0.166
CRP level, ≥5, n (%)	98 (87.5)	27 (96.4)	0.304
Oxygen saturation > 90, n (%)	97 (86.6)	17 (60.7)	0.002

DISCUSSION

AKI was the common outcome renal disease reported by studies in COVID-19, particularly among patients in the intensive care unit (ICU). The reported rates of AKI are extremely variable; however, available evidence suggests that it likely affects 0.5 to 40% of hospitalized patients and 50 to 80% of patients in the ICU (6-8).

Histopathological data relating to COVID-19 AKI are limited. The most common cause of acute kidney injury is seen as acute tubular injury in postmortem studies. Virus particles also damage tubular epithelium and podocyte. Importantly, complement activation and thrombotic microangiopathy are important mechanisms of kidney injury. COVID-19 is also associated with activation of an inflammatory response that has been termed a ‘cytokine storm’, which might contribute to the pathogenesis of COVID-19-associated multi-organ dysfunction. In studies reported that the virus causes collapsing glomerulopathy, which is a subtype of FSGS (in those with APOL1 gene variant), and glomerular diseases such as immunocomplex, ANCA-associated glomerulonephritis and IgA nephropathy. Activation of the renin-

angiotensin aldosterone system, hyperinflammatory response, hypercoagulability, and nonspecific factors such as hypotension and hypoxemia facilitate the development of AKI. Management of the disease in hospital and intensive care unit (dehydration, secondary infection, sepsis, etc.) also facilitates the development of acute kidney injury (9-13). In our study, sepsis (increased ferritin levels and lymphopenia) and hypoxemia were more prominent in the KDIGO 2,3 group.

Older age, chronic kidney disease (CKD), and the presence of other comorbidities (for example, diabetes mellitus, hypertension, obesity, heart failure and chronic obstructive pulmonary disease) are associated with worse outcomes and also represent risk factors for the development of AKI in patients with COVID-19. Renal replacement therapy used in 5% to 11% in hospitalized patients and 16% to 50% in ICU (14, 15). In our study, most of our patients had hypertension as a comorbid disease. However, 23.2% of KDIGO 1 group and 21.4% of KDIGO 2, 3 group had chronic kidney disease (acute kidney injury over chronic kidney disease). The need for renal replacement therapy developed in 39.3% of the patients in the KDIGO 2,3 group and 8.9% in the KDIGO 1 group. AKI progression was more evident in the KDIGO 2.3 group.

Mortality rate can be high in Covid 19 AKI patients. Studies shew that the mortality rate in Covid 19 KDIGO 2,3 AKI patients detected 11.2-91.7% (2, 3). We found AKI in 23% of our patients. The mortality rate was higher in these patients (13.6%), especially in the KDIGO 2, 3 group. Early diagnosis of the disease, hospitalization, comorbidities and management of critically ill patients affect mortality. In our country, effective treatment and hospitalization, efficient use of resources led to lower mortality rates.

In conclusion, COVID 19 affects many organ systems. The progression of the disease is especially serious in organ involvement such as renal involvement. AKI is the most common kidney disease in the course of the disease. Mortality is observed more in advanced AKI. Early diagnosis, effective treatment, hospitalization and follow-up in severe patients are important in the treatment of the disease.

References

1. <https://covid19.who.int/>. WHO Coronavirus (COVID-19) Dashboard.

2. Cheng Y, Luo R, Wang K, Zhang M, Wang Z et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int.* 2020;97(5):829-38.
3. Cheng Y, Luo R, Wang X, Wang K, Zhang N et al. The Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Adult Patients with Coronavirus Disease 2019. *Clin J Am Soc Nephrol.* 2020;15(10):1394-1402.
4. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. *Lancet.* 2019;394(10212):1949-1964.
5. Kellum JA, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL et al. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney International Supplements* (2012) 2, 2; doi:10.1038/kisup.2012.2.
6. Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, Rimmelé T et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. *Nat Rev Nephrol* 2020;16(12):747-64.
7. Ng JH, Bijol V, Sparks MS, Sise ME, Izzedine H and Jhaveri KD. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19. *Adv Chronic Kidney Dis.* 2020;27(5):365-76.
8. Kunutsora SK, Laukkanen J. Renal complications in COVID-19: a systematic review and meta-analysis. *Ann Med* 2020;52(7):345-53.
9. Moeinzadeh F, Dezfouli M, Naimi A, Shahidi S, Moradi H. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report. *Iran J Kidney Dis* 2020;14(3):239-42.
10. Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N. ANCA-associated vasculitis after COVID-19. *Rheumatol Int.* 2021;41(8):1523-29.
11. Sethi S, D'Costa MR, Hermann SM, Nasr SH, Fervenza FC. Immune-Complex Glomerulonephritis After COVID-19 Infection. *Kidney Int Rep.* 2021;6(4):1170-73.
12. Huang Y, Li XJ, Li YQ, Dai W, Shao T, Liu WY, Han M et al. Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report. *BMC Nephrol.* 2020;21(1):504.
13. Kooman JP, van der Sande FM. COVID-19 in ESRD and Acute Kidney Injury. *Blood Purif.* 2021;50(4-5):610-20.
14. Iwona Smarz-Widelska, Ewelina Grywalska, Izabela Morawska, Alicja Forma, Adam Michalski, Sebastian Mertowski, Rafał Hryniewicz et al. Pathophysiology and Clinical Manifestations of COVID-19-Related Acute Kidney Injury—The Current State of Knowledge and Future Perspectives. *Int J Mol Sci.* 2021; 22(13): 7082.

15. Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, Sutherland A et al.
AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-
19. J Am Soc Nephrol. 2021;32(1):161-76.